A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein: A, A' and A" are independently O, C=O, C-R' or N-R", where R' and R" may independently be H, amino, -NR 7 COR 6, COR 6, -CONR 7 R 8, C 1 -C 6 alkyl, or hydroxy(C 1 -C 6 alkyl)-, and R" may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A' and A" is O or C=O; R 0 and R are independently H, Br, Cl, F, or C 1 -C 6 alkyl; R 1 is H, C 1 -C 6 alkyl, or hydroxy(C 1 -C 6 alkyl)-; R 2 is selected from the group consisting of H, C 1 -C 6 alkyl-, C 1 -C 6 alkoxy-, hydroxy(C 1 -C 6 alkyl)-, phenyl(C 1 -C 6 alkyl)-, formyl, heteroaryl, heterocyclic, -COR 6, -OCOR 6, -COOR 6, -NR 7 COR 6, CONR 7 R 8, and -(CH 2) n -W, where W is cyano, hydroxy, C 3 -C 8 cycloalkyl, -SO 2 NR 7 R 8, and -SO 2 -R 9, where R 9 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, hydroxy, or C 1 -C 6 alkyl; X is C-R 3 or N, where R 3 may be H or C 1 -C 6 alkyl; R 4 and R 5 are independently H, amino, C 1 -C 6 alkyl, or hydroxy(C 1 -C 6 alkyl)-; R 6, R 7 and R 8 are each independently H, C 1 -C 6 alkyl, C 1 -C 4 alkoxy(C 1 -C 6 alkyl) or C 3 -C 8 cycloalkyl, said C 1 -C 6 alkyl is optionally substituted by halo, CN or hydroxy; or, R 7 and R 8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C 1 -C 6 alkyl; and, n is 0, 1, 2 or 3; for therapeutic use, wherein the compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, is administered orally. A, A' and A" are independently O, C=O, C-R' or N-R", where R' and R" may independently be H, amino, -NR 7 COR 6, COR 6, -CONR 7 R 8, C 1 -C 6 alkyl, or hydroxy(C 1 -C 6 alkyl)-, and R" may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A' and A" is O or C=O; R 0 and R are independently H, Br, Cl, F, or C 1 -C 6 alkyl; R 1 is H, C 1 -C 6 alkyl, or hydroxy(C 1 -C 6 alkyl)-; R 2 is selected from the group consisting of H, C 1 -C 6 alkyl-, C 1 -C 6 alkoxy-, hydroxy(C 1 -C 6 alkyl)-, phenyl(C 1 -C 6 alkyl)-, formyl, heteroaryl, heterocyclic, -COR 6, -OCOR 6, -COOR 6, -NR 7 COR 6, CONR 7 R 8, and -(CH 2) n -W, where W is cyano, hydroxy, C 3 -C 8 cycloalkyl, -SO 2 NR 7 R 8, and -SO 2 -R 9, where R 9 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, hydroxy, or C 1 -C 6 alkyl; X is C-R 3 or N, where R 3 may be H or C 1 -C 6 alkyl; R 4 and R 5 are independently H, amino, C 1 -C 6 alkyl, or hydroxy(C 1 -C 6 alkyl)-; R 6, R 7 and R 8 are each independently H, C 1 -C 6 alkyl, C 1 -C 4 alkoxy(C 1 -C 6 alkyl) or C 3 -C 8 cycloalkyl, said C 1 -C 6 alkyl is optionally substituted by halo, CN or hydroxy; or, R 7 and R 8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C 1 -C 6 alkyl; and, n is 0, 1, 2 or 3; for therapeutic use, wherein the compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, is administered orally.